Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81
Document › Details

Pierre Fabre S.A.. (3/21/19). "Press Release: Institut Curie and Pierre Fabre Strengthen Their Immuno-oncology Partnership". Paris & Castres.

Organisations Organisation Pierre Fabre Translational Medicine Department (Toulouse, IRPF)
  Group Pierre Fabre (Group)
  Organisation 2 Institut Curie
Products Product cancer immunotherapy (immuno-oncology, I-O)
  Product 2 drug discovery
Index term Index term Pierre Fabre–Institut Curie: cancer immunotherapy, 201903– collab extension I-O drug target discovery with IRPF
Persons Person Martin, Amaury (Institut Curie 201709 Technology Transfer + Industry Partnerships Office Director)
  Person 2 Chetaille, Eric (Pierre Fabre 201903 Director of Oncology Innovation Unit)

Building on the success of their first agreement entered into in 2017, Institut Curie and the Pierre Fabre Research Institute (IRPF) are renewing their partnership to identify new therapeutic strategies in immuno-oncology. The two partners aim to explore new molecular targets that are likely to adjust the immunity involved in controlling cancer development using models developed by Institut Curie in collaboration with IRPF based on human tumor cells.

"To build on the success of our first partnership initiated in 2017 with the Pierre Fabre Research Institute, we are going to launch a new joint project to understand the immune environment of tumors and better exploit it to combat cancer. We are going to involve a second team from Institut Curie's U932 Unit and focus on a detailed analysis of a new, innovative target using human cell models specifically developed for immuno-oncology research. Through this cooperation, we hope to provide a tangible contribution to developing a new therapeutic target for treating cancer patients using immunotherapy," explained Sebastian Amigorena, Director of the Cancer Immunotherapy Center at Institut Curie and Director of the Immunity and Cancer Research Unit (U932 Institut Curie / Inserm / Paris Descartes University).

"Pierre Fabre's expertise in oncology is based on 35 years' experience in the discovery, development, production and commercialization of new treatments. The strengthening of our strategic partnership with Institut Curie is in line with our commitment to providing transformative therapies for cancer patients. It will bring together the exceptional immuno-oncology expertise of Institut Curie's oncologists and biologists with our research and development teams' ability to quickly develop anti-cancer drug candidates on a new therapeutic target." stated Eric Chetaille (MD), Director of the Oncology Innovation Unit at Pierre Fabre.

"We're very pleased that the partnership initiated in 2017 with the Pierre Fabre teams has been as successful as expected and that it will continue for another 18 months. It is a great example of the value of establishing an open dialogue between academic research and industrial research. Companies such as Pierre Fabre have understood this and are seizing opportunities to participate in innovating in the highly-competitive immuno-oncology market," added Amaury Martin, Director of Technology Transfer and Industrial Partnership at Institut Curie and Director of Institut Carnot Curie Cancer.

Press contacts:

Fatima Hammouch - +33 (0)1 72 38 93 52 -

Valérie ROUCOULES - +33 (0)1 49 19 83 84 -

About the Cancer Immunotherapy Center at Institut Curie and the Immunity and Cancer Research Unit

Teams led by Sebastian Amigorena, Claire Hivroz and Philippe Benaroch are working towards a better understanding of the tumor microenvironment and interactions between tumors and the immune system, in order to use the immune system to combat cancer. Their projects range from understanding fundamental immunology in healthy individuals to more applied studies of immune responses to tumors, using animal models or human biological samples from cancer patients.

About Institut Curie

Institut Curie, a leading player in the fight against cancer, brings together a world-class research center and a state-of-the-art hospital complex for the treatment of all cancers, including the most rare forms. Founded in 1909 by Marie Curie, Institut Curie employs over 3,500 researchers, doctors and medical staff working on its three missions: care, research and knowledge transfer.
As a private institution of public interest authorized to accept donations and legacies, and through the support of its donors, Institut Curie can accelerate research findings and thus improve treatments and quality of life for patients.

To find out more:

Since 2011, Institut Curie is certified as "Institut Carnot Curie Cancer." The Carnot label is a label of excellence attributed to academic research structures, whose quality and commitment to partnership research have been proven. Curie Cancer gives industrial partners the opportunity to set up research partnerships drawing on the expertise of Institut Curie's staff in developing innovative therapeutic solutions to combat cancer, from therapeutic targets to clinical validation.

To find out more:

About Pierre Fabre

Present on a continuum of activities ranging from Rx pharmaceuticals to dermo-cosmetics products to consumer health care, the Pierre Fabre Group is the 2nd largest dermo-cosmetics laboratory in the world, the 2nd largest privately-owned French pharmaceutical group and the leader in France for OTC products sold in pharmacies. Its portfolio includes several international brands and franchises including Eau Thermale Avène, Klorane, Ducray, René Furterer, A-Derma, Galénic, Elancyl, Naturactive, Pierre Fabre Health Care, Pierre Fabre Oral Care, Pierre Fabre Dermatologie and Pierre Fabre Oncology.

In 2017, Pierre Fabre revenues totaled €2,318 million in net sales, 62% of which was generated by international sales and 61% by the dermo-cosmetics branch. Located in the Occitanie region since its creation, and headquartered in Castres in the Tarn department, the Group employs some 11,000 people worldwide and has subsidiaries or offices in 47 countries. Its products are distributed in over 130 countries. In 2017, Pierre Fabre dedicated almost €175 million to its R&D expenditure, shared between oncology, the central nervous system, consumer health care, dermatology and dermo-cosmetics.

86% of the Pierre Fabre Group is held by the Pierre Fabre Foundation, a government-recognized public-interest foundation since 1999, while a smaller share is owned by its employees, by means of an international employee stock ownership plan.

In 2015, AFNOR Certification assessed the corporate social and environmental responsibility approach of the Pierre Fabre Group as "exemplary" (AFAQ 26000 procedural document, based on the ISO 26000 standard on corporate and environmental social responsibility).

To find out more:

If you do not wish to receive any further e-mails, please click here

Record changed: 2019-04-16


Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

More documents for Pierre Fabre (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [iito] No Content Marketing 650x80px

» top